Phaseline

Targets › NTRK

NTRK: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2027.

Open in Phaseline: the race on NTRK, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Avistone BiotechnologyANS03
ROS1 and NTRK tyrosine kinase inhibitor
ROS1, NTRKPhase 1Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK AlterationDec 2027

Conditions

Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration (1)

Modalities

small molecule (1)

Companies

Avistone Biotechnology (1)

Related targets

ROS1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.